3-pyridylguanidine dihydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-pyridylguanidine dihydrochloride
• 英文别名: 1-(pyridin-3-yl)guanidine dihydrochloride；N-(3-Pyridinyl)guanidine dihydrochloride；N-pyridin-3-ylguanidine dihydrochloride；1-(Pyridin-3-yl)guanidine hydrochloride；2-pyridin-3-ylguanidine;hydrochloride
• 化学式: C₆H₈N₄*2ClH
• 分子量: 209.078
• InChiKey: ILJHFFBCQQDQIP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.81
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  77.3
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-pyridylguanidine dihydrochloride 在 硝酸 作用下， 以 硫酸 为溶剂， 生成 N"-nitro-N-(3-pyridinyl)guanidinium nitrate
  参考文献：
  名称：

  Potassium channel openers

  摘要：

  公式I的化合物： 在预防或用钾通道开放剂改善的疾病治疗中有用。还公开了钾通道开放组合物和一种在哺乳动物中开放钾通道的方法。

  公开号：

  US06645968B2
• 作为产物：
  描述：

  1-(pyridin-3-yl)-2,3-di(tert-butoxycarbonyl)guanidine 在 盐酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 异丙醇 为溶剂， 以85%的产率得到3-pyridylguanidine dihydrochloride
  参考文献：
  名称：

  α 2 -肾上腺素能受体拮抗剂：合成，药理学评价，并Pyridinoguanidine的分子模拟研究，吡啶并-2- aminoimidazoline及其衍生物

  摘要：

  我们先前已经确定苯基胍和苯基-2- aminoimidazoline化合物作为高亲和力配体与在α相冲突的功能活性2 -肾上腺素能受体，G蛋白偶联受体与相关性在几个神经精神病症。在本文中，我们描述了一系列新的吡啶衍生物[对位取代的2-和3-胍基和2-和3-（2-氨基咪唑啉代）吡啶，双取代的2-胍基吡啶和N-取代的吡啶衍生物的设计，合成和药理学评估-2-氨基-1,4-二氢喹唑啉]被认为是拮抗剂/α的逆激动剂2 -肾上腺素受体。此外，所述化合物在α发挥它们的作用2微量透析实验显示，人前额叶皮层组织中的β-肾上腺素受体和大鼠脑中的体内β-肾上腺素能受体都是如此。我们还提供了在α对接研究2A -和α 2C -肾上腺素能受体亚型显示出高亲和力结合受体所需的结构特征。

  DOI：

  10.1021/jm501635e

文献信息

• Compounds and methods for inhibiting mitotic progression
  申请人：Claiborne F. Christopher

  公开号：US20050256102A1

  公开（公告）日：2005-11-17

  This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.

  这项发明涉及用于治疗癌症的化合物和方法。具体而言，该发明提供了抑制枢纽激酶的化合物，包含这些化合物的药物组合物，以及利用这些化合物治疗癌症的方法。
• The Use of Chloroformamidine Hydrochloride as a Reagent for the Synthesis of Guanidines from Electron Deficient Aromatic Amines
  作者：Ian Armitage、Mingkun Fu、Frederick Hicks、Adiseshu Kattuboina、Jennifer S. N. Li、Ashley McCarron、Lei Zhu

  DOI：10.1002/jhet.2567

  日期：2017.1

  compound, a clean, efficient approach to guanidine synthesis using chloroformamidine hydrochloride was identified. To investigate the general utility of this methodology towards electron‐deficient aromatic amines, a set of favorable conditions were developed from a series of screens, and the scope of the reaction was probed. The successful application of this chemistry to a variety of pyridines, anilines

  为了优化内部显影剂的制造工艺，已确定了使用盐酸氯甲am盐的一种清洁，有效的胍合成方法。为了研究这种方法对缺电子的芳族胺的一般用途，通过一系列筛选开发了一系列有利条件，并探查了反应范围。该化学方法成功应用于各种吡啶，苯胺和杂环化合物中，突显了其作为一种改良的，可替代的鸟苷酸化方法的用途，可用于这套通常具有挑战性的芳香族胺。
• Design and synthesis of novel cyanoguanidine ATP-sensitive potassium channel openers for the treatment of overactive bladder
  作者：Arturo Perez-Medrano、Steven A. Buckner、Michael J. Coghlan、Robert J. Gregg、Murali Gopalakrishnan、Michael E. Kort、John K. Lynch、Victoria E. Scott、James P. Sullivan、Kristi L. Whiteaker、William A. Carroll

  DOI：10.1016/j.bmcl.2003.10.063

  日期：2004.1

  potassium channel openers through high-throughput screening. Based on these findings, a number of novel cyanoguanidines were designed and synthesized, which hyperpolarized human bladder K(ATP) channels. These agents are potent full agonists in relaxing electrically-stimulated pig bladder strips. The synthesis, SAR and biological properties of these agents are discussed.

  通过高通量筛选，硫脲衍生物被确定为格列本脲可逆的钾通道开放剂。基于这些发现，设计并合成了许多新的氰基胍，它们使人膀胱K（ATP）通道超极化。这些药物在放松电刺激的猪膀胱带中是有效的完全激动剂。讨论了这些试剂的合成，SAR和生物学特性。
• [EN] PYRIDINYLAMINO-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS<br/>[FR] DERIVES DE PYRIDINYLAMINO-PYRIMIDINE UTILES COMME INHIBITEURS DE LA PROTEINE KINASE
  申请人：CYCLACEL LTD

  公开号：WO2005012298A1

  公开（公告）日：2005-02-10

  The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, wherein: (A) 'a' is a single bond and 'b' is a double bond; R1 and R2 are each independently as defined below; R10 is absent; or (B) 'a' is a double bond and 'b' is a single bond; R1 is oxygen; R2 is as defined below; and R10 is H or alkyl; X is S, O, NH, or NR 7; Y is N or CR8; one of Z1, Z2, and Z3 is N or N+Ra and the remainder are each independently CR7; R1, R2, R5 and R6 are each independently R7; R3 and R4 are each independently R8; each R7 is independently H, halogen, NRbRC, ORd or a hydrocarbyl group optionally substituted by one or more R9 groups; each R8 is independently H or (CH2)R9, where n is 0 or 1; each R9 is independently selected from H, halogen, NO2, CN, Re, NHCORf, CF3, CORg, NRhRi, CONRJRk, SO2NR1Rm, SO2Rn, ORp, OCH2CH2ORq, morpholine, piperidine and piperazine; and Ra-q are each independently H or alkyl, wherein said alkyl group is optionally substituted by one or more R9 groups; where the compound is other than [4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-yl]-pyridin­2-yl-amine and 4-[4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-N-4­pyridinyl-2-pyrimidinamine. Further aspects of the invention relate to the use of compounds of formula I in the treatment of proliferative disorders, viral disorders, CNS disorders, strokes, alopecia and/or diabetes.

  本发明涉及式I的化合物或其药学上可接受的盐，其中：（A）'a'为单键，'b'为双键；R1和R2各自独立定义如下；R10不存在；或（B）'a'为双键，'b'为单键；R1为氧原子；R2如下定义；R10为H或烷基；X为S、O、NH或NR7；Y为N或CR8；Z1、Z2和Z3中的一个为N或N+Ra，其余各自独立为CR7；R1、R2、R5和R6各自独立为R7；R3和R4各自独立为R8；每个R7各自独立为H、卤素、NRbRC、ORd或一个或多个R9基团可选择地取代的烃基；每个R8各自独立为H或（CH2）R9，其中n为0或1；每个R9各自独立选择自H、卤素、NO2、CN、Re、NHCORf、CF3、CORg、NRhRi、CONRJRk、SO2NR1Rm、SO2Rn、ORp、O ORq、吗啡啉、哌啶和哌嗪；而Ra-q各自独立为H或烷基，其中所述的烷基可以选择地被一个或多个R9基团取代；其中该化合物不是[4-(2,4-二甲基噻唑-5-基)嘧啶-2-基]-吡啶-2-基-胺和4-[4-氟苯基)-1-(1-甲基-4-哌啶基)-1H-咪唑-5-基]-N-4-吡啶基-2-嘧啶胺。本发明的进一步方面涉及使用式I的化合物治疗增殖性疾病、病毒性疾病、中枢神经系统疾病、中风、脱发和/或糖尿病。
• Structure−Activity Relationships for the Binding of Arylpiperazines and Arylbiguanides at 5-HT₃ Serotonin Receptors
  作者：Małgorzata Dukat、Ashraf A. Abdel-Rahman、Abd M. Ismaiel、Stacy Ingher、Milt Teitler、Laszlo Gyermek、Richard A. Glennon

  DOI：10.1021/jm9603936

  日期：1996.1.1

  Arylpiperazines are nonselective agents that bind at 5-HT3 serotonin receptors with moderate to high affinity, whereas 1-phenylbiguanide is a low-affinity but more selective 5-HT3 agonist. In an attempt to enhance the affinity of the latter agent, and working with the assumption that similarities might exist between the binding of the two types of agents, we formulated structure-activity relationships for the binding of the arylpiperazines and then incorporated those substituents, leading to high affinity for the arylpiperazines, into 1-phenylbiguanide. A subsequent investigation examined the structure-activity relationships of the arylbiguanides and identified arylguanidines as a novel class of 5-HT3 ligands. Although curious similarities exist between the structure-activity relationships of the arylpiperazines, arylbiguanides, and arylguanidines, it cannot be concluded that all three series of compounds are binding in the same manner. Furthermore, upon investigating pairs of compounds in the three series, the arylpiperazines behaved as 5-HT3 antagonists (von Bezold-Jarisch assay) whereas the arylbiguanides and arylguanidines acted as 5-HT3 agonists.